Mitchell Chan
Director/Board Member bei AVALO THERAPEUTICS, INC.
Profil
Mitchell Chan is an Independent Director at Avalo Therapeutics, Inc. and a Director at Maryland Technology Council.
He was previously a Director-Investor Relations at AstraZeneca PLC and the Chief Financial & Accounting Officer at Viela Bio, Inc. He holds an MBA from Rotman School of Management and undergraduate and graduate degrees from the University of Toronto.
Aktive Positionen von Mitchell Chan
| Unternehmen | Position | Beginn |
|---|---|---|
| AVALO THERAPEUTICS, INC. | Director/Board Member | 01.12.2021 |
Maryland Technology Council
 Maryland Technology Council Miscellaneous Commercial ServicesCommercial Services The Maryland Technology Council functions as a technology trade association. The private company is based in Rockville, MD. | Director/Board Member | 11.03.2020 |
Ehemalige bekannte Positionen von Mitchell Chan
| Unternehmen | Position | Ende |
|---|---|---|
| VIELA BIO, INC. | Director of Finance/CFO | 15.03.2021 |
| ASTRAZENECA PLC | Investor Relations Contact | - |
Ausbildung von Mitchell Chan
| Rotman School of Management | Masters Business Admin |
| University of Toronto | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| AVALO THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Maryland Technology Council
Maryland Technology Council Miscellaneous Commercial ServicesCommercial Services The Maryland Technology Council functions as a technology trade association. The private company is based in Rockville, MD. | Commercial Services |
Viela Bio, Inc.
 Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
